LEADING EDGE BIO

Lessons from Antibodies, Peptides, AI, and Cell Therapy Every biotechnology company believes it has a platform. Far fewer have one that large pharmaceutical companies actually want to partner. Over the past two decades, I've watched our industry transform through successive waves of innovation, from monoclonal antibodies and directed evolution to cell therapy, gene therapy, AI-enabled drug discovery, and programmable biologics. Some platforms generated billions of dollars in

For the past decade, biopharma companies have invested heavily in artificial intelligence to improve target identification, protein engineering, clinical trial design, biomarker discovery, pathology, pharmacovigilance, and commercial operations. Until recently, however, relatively little attention was paid to governing those AI systems. That era is ending. The emergence of healthcare AI governance frameworks—including certification programs and industry playbooks—signals that

One of the more fascinating opportunities I encountered recently involved a highly academic organization developing an AI-driven platform intended to transform how biomedical research and pathology data are interpreted. The science was exceptional. The team consisted of world-class researchers. The technology held genuine promise to accelerate biomarker discovery, improve translational research, and ultimately support more precise drug development. The challenge wasn't the sc